Is this consistent with "legacy effect"? the patients who...

Is this consistent with "legacy effect"? the patients who received DMX in this period received PBO previously, so how would they show some persistence of effect? Or am I missing something here. The press release is unfortunately not perticularly clear. Doesnt the fact that the "second baseline" value for the PBO group in fig 2 is close to zero suggest there is no legacy effect, given that these patients are the ones who were on DMX 6 weeks previously? Let me know if I've miss read this.

i never thought the "legacy effect" stuff sounded perticularly robust.

the study design looks like a way of getting a second bite at the Apple with a single patient cohort, whilst boosting recruitment as all patients know they will receive study drug.

this reads as positive to me and shows a greater treatment effect than the first study period, which is readily attributable to the variability of disease and small patient population.

question would then be, was period 2 fortunate to show a larger treatment effect, or was period 1 unfortunate to show a small one. Perhaps a bit of both?

all in all, encouraging result